SARS-CoV-2 spike protein mutations: Difference between revisions
Jump to navigation
Jump to search
Eric Martz (talk | contribs) No edit summary |
Eric Martz (talk | contribs) No edit summary |
||
| Line 106: | Line 106: | ||
*February 8, 2021: Added halting of use of Astra-Zenica vaccine in South Africa<ref name="haltsa" />. Changed most mentions of 501.V2 to 501Y.V2 as this terminology seems to have become predominant. | *February 8, 2021: Added halting of use of Astra-Zenica vaccine in South Africa<ref name="haltsa" />. Changed most mentions of 501.V2 to 501Y.V2 as this terminology seems to have become predominant. | ||
*February 16, 2021: Cited mutations at position 677<ref name="s677" />. Cited evidence for increased virulence of B.1.1.7<ref name="nervtag2" />. | *February 16, 2021: Cited mutations at position 677<ref name="s677" />. Cited evidence for increased virulence of B.1.1.7<ref name="nervtag2" />. | ||
*February 17, 2021: Cited list of >700 defined lineages<ref name="a." /><ref name="pango" />. | *February 17, 2021: Cited list of >700 defined lineages<ref name="a." /><ref name="pango" />. Used lineage nomenclature where feasible. B.1.1.7 now in 83 countries<ref name="b.1.1.7" />. | ||
==See Also== | ==See Also== | ||